Patents by Inventor Cassandra Parent

Cassandra Parent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12105099
    Abstract: This disclosure provides methods and devices for determining a quantitative estimate of syndecan-1 levels in a mammalian subject suspected of internal hemorrhaging. The method includes applying a blood sample from the subject to a hand-held assay device capable of providing optical quantitation of the amount of syndecan-1 in the sample, measuring, by means of said assay device, an analyte signal value correlated to a concentration of the syndecan-1 in the blood sample and comparing the analyte signal value to a minimum threshold, wherein an analyte signal value less than the minimum threshold indicates that the subject is not internally hemorrhaging, and an analyte signal value above the minimum threshold indicates the subject is internally hemorrhaging. The methods and devices are adapted to rapidly assess internal hemorrhaging and hemorrhagic shock in a patient outside of hospital settings.
    Type: Grant
    Filed: April 7, 2022
    Date of Patent: October 1, 2024
    Assignee: DIOTEX DIAGNOSTICS, LLC
    Inventors: Richard Eng, Cassandra Parent, Amal Hayat, Amanda Ruci, Anvith Krishnan, Feiyang Huang, Eric Simon, Ellie Zhang
  • Publication number: 20220349905
    Abstract: This disclosure provides methods and devices for determining a quantitative estimate of syndecan-1 levels in a mammalian subject suspected of internal hemorrhaging. The method includes applying a blood sample from the subject to a hand-held assay device capable of providing optical quantitation of the amount of syndecan-1 in the sample, measuring, by means of said assay device, an analyte signal value correlated to a concentration of the syndecan-1 in the blood sample and comparing the analyte signal value to a minimum threshold, wherein an analyte signal value less than the minimum threshold indicates that the subject is not internally hemorrhaging, and an analyte signal value above the minimum threshold indicates the subject is internally hemorrhaging. The methods and devices are adapted to rapidly assess internal hemorrhaging and hemorrhagic shock in a patient outside of hospital settings.
    Type: Application
    Filed: April 7, 2022
    Publication date: November 3, 2022
    Inventors: Richard Eng, Cassandra Parent, Amal Hayat, Amanda Ruci, Anvith Krishnan, Feiyang Huang, Eric Simon, Ellie Zhang